| |
| |
| |
| Basis of Disease Pathogenesis | |
| |
| |
| |
| Genetics | |
| |
| |
| |
| Major histocompatibility complex class II | |
| |
| |
| |
| |
| Genetic susceptibility and class III complement genes | |
| |
| |
| |
| |
| Constitutive genes and lupus | |
| |
| |
| |
| |
| Genetics of lupus in mice | |
| |
| |
| |
| |
| Tolerance and autoimmunity | |
| |
| |
| |
| |
| Dendritic cells in SLE | |
| |
| |
| |
| |
| T cells and systemic lupus erthematosus | |
| |
| |
| |
| |
| B-lymphocyte biology in SLE | |
| |
| |
| |
| |
| Polymorhonuclear and endothelial cells | |
| |
| |
| |
| |
| Mechanisms and consequences of mitochondrial dysfunction and oxidative stress in T cells of patients with SLE | |
| |
| |
| |
| |
| Cell cycle regulation and systemic lupus erythematosus | |
| |
| |
| |
| |
| The role of reactive nitrogen and oxygen intermediates in systemic lupus erythematosus | |
| |
| |
| |
| |
| Origins of antinuclear antibodies | |
| |
| |
| |
| |
| Anti-DNA antibodies: Structure, regulation and pathogenicity | |
| |
| |
| |
| |
| Extractable nuclear antigens and SLE: specificity and role in disease pathogenesis | |
| |
| |
| |
| |
| Antihistone and antispliceosomal antibodies | |
| |
| |
| |
| |
| Toll-like receptors in SLE | |
| |
| |
| |
| |
| Interferon-alpha in systemic lupus erythematosus | |
| |
| |
| |
| |
| Immune complexes in systemic lupus erythematosus | |
| |
| |
| |
| |
| Complement and tissue injury in SLE | |
| |
| |
| |
| |
| Humoral pathogenesis: Fc receptors in autoimmunity and end-organ damage | |
| |
| |
| |
| |
| Environmental Aspects of Pathogenesis | |
| |
| |
| |
| Drug-induced lupus mechanisms | |
| |
| |
| |
| |
| Gender and age in lupus | |
| |
| |
| |
| |
| Roles for infections in systemic lupus erythematosus pathogenesis | |
| |
| |
| |
| |
| Systemic lupus erythematosus in domestic animals | |
| |
| |
| |
| |
| Mechanisms of Tissue Injury | |
| |
| |
| |
| Pathogenesis of lupus nephritis | |
| |
| |
| |
| |
| Tissue injury and the skin | |
| |
| |
| |
| |
| Neuropsychiatric systemic lupus erythematosus: Mechanisms of injury | |
| |
| |
| |
| |
| Atherosclerosis and tissue injury in systemic lupus erythematosus | |
| |
| |
| |
| |
| Clinical Aspects of Disease | |
| |
| |
| |
| Clinical Presentation | |
| |
| |
| |
| The clinical presentation of systemic lupus erythematosus | |
| |
| |
| |
| |
| Neonatal lupus | |
| |
| |
| |
| |
| SLE in children | |
| |
| |
| |
| |
| Drug-induced disease | |
| |
| |
| |
| |
| Laboratory evaluation of patients with systemic lupus erythematosus | |
| |
| |
| |
| |
| Pregnancy and reproductive concerns in systemic lupus erythematosus | |
| |
| |
| |
| |
| Epidemiology of systemic lupus erythematosus | |
| |
| |
| |
| |
| Monitoring disease activity | |
| |
| |
| |
| |
| Incomplete lupus erythematosus | |
| |
| |
| |
| |
| Design of clinical trials for SLE | |
| |
| |
| |
| |
| Organ Systems | |
| |
| |
| |
| The nervous system and lupus | |
| |
| |
| |
| |
| Skin | |
| |
| |
| |
| |
| Kidney | |
| |
| |
| |
| |
| Heart | |
| |
| |
| |
| |
| Vasculitis | |
| |
| |
| |
| |
| Lung | |
| |
| |
| |
| |
| Gastrointestinal: Liver | |
| |
| |
| |
| |
| Gastrointestinal: Nonhepatic | |
| |
| |
| |
| |
| Cellular hematology | |
| |
| |
| |
| |
| Musculoskeletal system: Articular disease, bone metabolism | |
| |
| |
| |
| |
| Anti-Phospholipid Syndrome | |
| |
| |
| |
| Pathogenesis | |
| |
| |
| |
| Antiphospholipid antibody: Pathogenesis | |
| |
| |
| |
| |
| Endothelial cell damage and atherosclerosis | |
| |
| |
| |
| |
| Clinical | |
| |
| |
| |
| Laboratory testing for antiphospholipid syndrome | |
| |
| |
| |
| |
| Clinical presentation of antiphospholipid syndrome | |
| |
| |
| |
| |
| Pregnancy and antiphospholipid syndrome | |
| |
| |
| |
| |
| Treatment of antiphospholipid syndrome | |
| |
| |
| |
| |
| Treatment | |
| |
| |
| |
| Steroids and nonsteroidal anti-inflammatory drugs | |
| |
| |
| |
| |
| Antimalarials | |
| |
| |
| |
| |
| Cytotoxic agents | |
| |
| |
| |
| |
| Biological agents | |
| |
